\nCompania german\u0103 de biotehnologie CureVac a \u00eenrolat primul participant pentru a doua etap\u0103 a fazei doi din testele clinice pentru testarea poten\u0163ialului vaccin \u00eempotriva Covid-19 dezvoltat de nem\u0163i, conform unui anun\u0163 lansat ast\u0103zi, citat de Reuters.<\/p>\n
\nAceast\u0103 etap\u0103 a testelor clinice este important\u0103 \u00een vederea aprob\u0103rii ulterioare, \u00eentruc\u00e2t este analizat\u0103 at\u00e2t siguran\u0163a, c\u00e2t \u015fi eficien\u0163a la adul\u0163i \u015fi urmeaz\u0103 s\u0103 includ\u0103 peste 35.000 de participan\u0163i din Europa \u015fi America Latin\u0103.<\/p>\n
\nTestele ar trebui s\u0103 demonstreze eficien\u0163a vaccinului \u00een prevenirea infect\u0103rii cu noul coronavirus, a anun\u0163at CureVac.<\/p>\n
\n\u201eDatele legate de siguran\u0163\u0103 \u015fi imunogenitate (n.red: capacitatea de a declan\u015fa un r\u0103spuns imun) arat\u0103 promi\u0163\u0103tor p\u00e2n\u0103 \u00een acest moment \u015fi sper\u0103m ca aceste teste vor continua s\u0103 demonstreze impactul tehnologiei mRNA \u015fi efectul vaccinului nostru \u00een prevenirea Covid-19, pentru a putea \u00eenvinge aceast\u0103 pandemie\u201d, a transmis Franz-Werner Haas, directorul executiv al CureVac.<\/p>\n
\nPoten\u0163ialul vaccin dezvoltat de CureVac este unul dintre cele trei proiecte pe care guvernul german le sus\u0163ine cu o finan\u0163are total\u0103 de circa 750 milioane de euro.<\/p>\n
\nComisia European\u0103 a rezervat deja 405 milioane de doze din poten\u0163ialul vaccin dezvoltat de CureVac.<\/p>\n","protected":false},"excerpt":{"rendered":"
Compania german\u0103 de biotehnologie CureVac a \u00eenrolat primul participant pentru a doua etap\u0103 a fazei doi din testele clinice pentru testarea poten\u0163ialului vaccin \u00eempotriva Covid-19 dezvoltat de nem\u0163i, conform unui anun\u0163 lansat ast\u0103zi, citat de Reuters. Aceast\u0103 etap\u0103 a testelor clinice este important\u0103 \u00een vederea aprob\u0103rii ulterioare, \u00eentruc\u00e2t este analizat\u0103 at\u00e2t siguran\u0163a, c\u00e2t \u015fi eficien\u0163a […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[272,7442,274,10130,9356,14930],"class_list":["post-188967","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-companie","tag-dezvoltare","tag-incepere","tag-potential","tag-teste","tag-vaccin"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/188967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=188967"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/188967\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=188967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=188967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=188967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}